Aktieanalys

Medivir Q2 2025: Awaiting Phase IIb - Redeye

{newsItem.title}

Redeye Publicerad: 22 Aug 13:50

Redeye comments on Medivir’s Q2 report. The quarter was somewhat uneventful, but the company has made further progress and is essentially ready for the planned pivotal phase II study in liver cancer. The only thing missing is funding.

Länk till analysen i sin helhet: https://www.redeye.se/research/1124142/medivir-q2-2025-awaiting-phase-iib?utm_source=finwire&utm_medium=RSS

Nyheter om Medivir

Läses av andra just nu

Om aktien Medivir

Senaste nytt